**Supplementary Appendix**

*Albuminuria lowering effect of eplerenone, dapagliflozin and their combination in patients with chronic kidney disease*

**Content:**

**Supplement 1:** Full list of ROTATE-3 Investigators

**Table 1:** Percent change from baseline in 24-hour urinary albumin excretion at week 4

**Table 2:** UACR change after adjustment for concomitant blood pressure and body weight changes

**Figure 1:** Trial profile

**Figure 2:** Changes in systolic blood pressure in patient subgroups during treatment with dapagliflozin, eplerenone and dapagliflozin-eplerenone

**Figure 3:** Changes in eGFR in patient subgroups during treatment with dapagliflozin, eplerenone and dapagliflozin-eplerenone

**Appendix 1: ROTATE-3 Investigators**

*Italy -* University of Campania, Naples, Italy

* Luigi Pennino
* Ilaria De Gregorio
* Lucio Polese
* Alfredo Caturano
* Roberto Minutolo
* Ferdinando Sasso

*Italy – University of* Catanzaro, Catanzaro, Italy

* Ida Gagliardi,
* Mariateresa Zicarelli
* Giuseppina Crugliano

*Spain –* Clinic University hospital, INCLIVA Health Research Institute Valencia Spain

* Elena Gimenez Civera
* Nayara Panizo

*Netherlands –* University of Groningen, Groningen, Netherlands

* Taha Sen
* Di Xie

**Supplement table 1:** Percent change from baseline in 24-hour urinary albumin excretion at week 4 (95% confidence interval)

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Dapagliflozin** | **Eplerenone** | **Dapagliflozin-eplerenone** |
| Change from baseline | -19.2% (-34.2, -0.9) | -34.2 (-46.7, -18.9) | -52.9 (-61.7, -42.1) |
| Difference vs dapagliflozin |  | -22.8 (-60.4, 5.9)P=0.1290 | -41.7 (-55.1, -24.3)P=<0.0001 |
| Difference vs eplerenone |  |  | -28.4 (-45.2, -6.5)P=0.0149 |

**Supplement table 2:** UACR change after adjustment for concomitant blood pressure and body weight changes

|  |  |  |
| --- | --- | --- |
|  | **Dapagliflozin-eplerenone vs dapagliflozin** | **Dapagliflozin-eplerenone vs eplerenone** |
| No adjustment | -41.6 (-55.2, -23.9) | -29.1 (-45.8, -7.3) |
| Adjustment for systolic blood pressure | -39.6 (-53.7, -21.1) | -26.8 (-44.1, -4.2) |
| Adjustment for body weight | -41.7 (-24.3, -55.1) | -28.4 (-45.2, -6.5) |
| Adjustment systolic blood pressure and body weight | -39.6 (-53.6, -21.5) | -25.9 (-43.2, -3.1) |

**Figure 1:** Trial profile

****

One patient withdrew consent after completing 2 treatment periods; one patient withdrew consent during the first treatment period.

**Figure 2:** Changes in systolic blood pressure in patient subgroups during treatment with dapagliflozin, eplerenone and dapagliflozin-eplerenone

****

**Figure 3:** Changes in eGFR in patient subgroups during treatment with dapagliflozin, eplerenone and dapagliflozin-eplerenone

****